Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
February 2017
-
Media ReleaseSandoz Pharmaceuticals AG als Top-Arbeitgeber Schweiz 2017 ausgezeichnetSandoz Pharmaceuticals AG wurde offiziell vom Top Employers Institute für ihr hervorragendes Mitarbeiterangebot in der Schweiz ausgezeichnet Die jährliche internationale Forschungstätigkeit des…
-
Featured NewsMedical researchers using new tools to turn science fiction into science fact
Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.
January 2017
-
Media ReleaseNovartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSCVotubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC) Approval addresses unmet…
-
Countering the genome reprogramming of cancer cells
Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model
-
Media ReleaseNovartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance ReportNovartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program Novartis improved position in…
-
Media ReleaseAlcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgeryInnovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers…
-
Featured NewsNovartis 2016 Financial Results
-
Media ReleaseNovartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buybackFY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster status Entresto (USD 170 million) continued to grow…
-
Media ReleaseNovartis: solide performance en 2016, les produits de croissance[1] absorbant la perte d'exclusivité de Gleevec aux USA; dynamique continue d'innovation; rachat d'actions annoncéChiffre d'affaires net de l'exercice 2016 (0% tcc[2]) comparable à celui de l'exercice précédent, grâce à l'excellente performance des produits de croissance Cosentyx (USD 1,1 milliard) a…
-
Media ReleaseNovartis erzielt 2016 solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust der Exklusivrechte für Gleevec in den USA wettmachen; Innovationsdynamik hält an; Aktienrückkauf angekündigtDer Nettoumsatz (0% kWk[2]) bleibt im Gesamtjahr dank starker Performance der Wachstumsprodukte auf Vorjahresniveau Cosentyx (USD 1,1 Milliarden) erreicht Blockbuster-Status Entresto (USD 170…
-
Featured NewsImproving diabetes awareness and treatment adherence in India
Through a successful patient support program, Novartis is taking diabetes care beyond the pill in India.
-
Women in Science: Virginia Lazala
Lazala has been recognized by Hispanic Executive magazine for her commitment to mentoring students and colleagues.
Pagination
- ‹ Previous page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- …
- 152
- › Next page